Passion for Innovation. Compassion for Patients.™



Results Briefing Results for Q1 FY2015 (April 1 – June 30, 2015)

DAIICHI SANKYO CO., LTD

Joji Nakayama President and CEO

July 31, 2015



FY2015 Q1 Results

FY2015 revised consolidated forecast

Edoxaban update

R&D Topics



FY2015 Q1 Results

Overview of FY2015 Q1 Results



	FY2014 Q1 Results * ¹	FY2015 Q1 Results	ΥοΥ
Revenue	213.7	238.4	+11.6% + 24.7
Cost of Sales	64.6	74.0	+9.4
SG&A Expenses	74.9	71.6	-3.3
R&D Expenses	41.4	43.7	+2.3
Operating Profit	32.8	49.1	+49.8% + 16.3
Profit before tax	32.7	45.2	+12.5
Profit attributable to owners of the Company	21.6	34.9	+61.9% + 13.4
Currency USD/JPY	102.16	121.37	+19.21
Rate EUR/JPY	140.06	134.16	-5.9

*1 FY2014 Q1 Results have been restated and indicated as only the values for continuing operations excluding Ranbaxy.


FY2015 Q1 Revenue



Negative

Factors

Increased by 24.7 JPY Bn Decline in Daiichi Sankyo Inc. and Daiichi Sankyo Europe offsetted by growth of Japan, Luitpold and ASCA with Forex




FY2015 Q1 Operating Profit


Positive Factors




Negative

Factors







Major business units



(JPY Bn)

	FY2014 Q1 Results	FY2015 Q1 Results	ΥοΥ	vs. Forecast (%)
Japan	108.0	114.2	+6.2	23%
Daiichi Sankyo Healthcare	9.4	10.8	+1.4	23%
Daiichi Sankyo Inc.	41.6	48.0	+6.4	29%
Olmesartan	25.7	28.8	+3.1	29%
Welchol	11.3	13.5	+2.2	37%
Effient	4.2	5.2	+1.0	-
Savaysa	-	-0.3	-0.3	-
Movantik	-	0.2	+0.2	-
Luitpold	12.5	21.5	+9.1	28%
Venofer	7.2	9.1	+1.9	33%
Injectafer	1.5	3.9	+2.4	23%
Daiichi Sankyo Europe	24.5	20.2	-4.3	27%
Olmesartan	19.7	15.8	-3.9	28%
Efient	1.2	1.1	-0.0	-
Lixiana	-	0.0	+0.0	1%
Asia, South and Central America (ASCA)	15.1	21.4	+6.3	24%

Major products in Japan



					(JPY Bn)
		FY2014 Q1 Results	FY2015 Q1 Results	YoY	vs. Forecast (%)
Olmetec	anti-hypertension	18.7	18.5	-0.3	23%
Nexium	anti-ulcer (Proton Pump Inhibitor)	15.3	19.1	+3.8	26%
Memary	treatment for Alzheimer	7.9	10.2	+2.4	22%
Loxonin	analgesic and anti- inflammatory	12.2	12.6	+0.3	29%
Cravit	antibacterial	6.9	4.6	-2.3	27%
Rezaltas	anti-hypertension	4.5	4.6	+0.1	24%
Artist	anti-hypertension	4.8	4.1	-0.7	24%
Omnipaque	contrast medium	4.2	4.2	-0.0	26%
Mevalotin	anti-hyperlipidemia	4.2	3.6	-0.6	26%
Ranmark	treatment for bone metastasis	2.1	2.9	+0.8	22%
Urief	treatment for dysuria	2.7	2.9	+0.1	26%
Pralia	osteoporosis	1.3	2.6	+1.3	26%
Lixiana	anticoagulant	0.1	2.1	+2.0	19%
Efient	antiplatelet	0.2	1.2	+1.0	23%
Teneria	treatment for type 2 diabetes	1.5	2.4	+0.9	-



FY2015 revised consolidated forecast

FY2015 revised consolidated forecast



				(JPY Bn)	
		FY 2015 Original Forecast (May)	FY 2015 Revised Forecast (July)	vs. Original Forecast	
Revenue		920.0	950.0	+30.0	Due to delay of launch of GE products for Welchol and further expansion in
Cost of Sale	S	300.0	302.0	+2.0	some products including Injectafer
SG&A Exper	ises	330.0	338.0	+8.0	
R&D Expens	ies	190.0	190.0	0.0	Due to further investment for increasing sales in the
Operating	j Profit	100.0	120.0	+20.0	U.S.
Profit bef	ore tax	95.0	115.0	+20.0	
Profit attrik owners of t	butable to the Company	60.0	75.0	+15.0	
		100.00	100.04	7 Fore	cast for Q2, Q3 and Q4
Currency Rate	USD/JPY EUR/JPY	120.00 130.00	120.34 131.04		JPY:120 EUR/JPY:130
	EUR/JP1	130.00	131.04		

Summary of revised revenue forecast



	(JPY Bn)				
	FY 2015 Original Forecast (May)	FY 2015 Revised Forecast (July)	vs. Original Forecast	Sales forecast in Japan	
Japan	488.0	488.0	- `	remains the same as May, although some products has been revised	
Olmetec	80.0	79.0	-1.0		
Cravit	21.0	17.0	-4.0	Welchol;	
Lixiana	5.0	11.0	+6.0	Due to delay of GE products entry	
Daiichi Sankyo Inc.	140.0	166.0	+26.0	Savaysa;	
Welchol	9.0	37.0	+28.0	Taking the situation of negotiation with payers into account	
Savaysa	4.0	2.0	-2.0		
Luitpold	72.0	76.0	+4.0	Venofer and Injectafer;	
Venofer	27.0	28.0	+1.0	Further growth	
Injectafer	15.0	17.0	+2.0		



Edoxaban update

Edoxaban update



Launch and development for making Edoxaban a flagship product after olmesartan Global sales forecast in FY2015: 14.7 JPY Bn

- Making a good start (especially in VTE)
- Revised sales forecast (5.0 JPY $Bn \rightarrow 11.0$ JPY Bn)

US

JPN

- Negotiation with payers to be listed in formularies of Part-D is on going
- Revised sales forecast (4.0 JPY Bn→2.0 JPY Bn)

🔅 EU

- Launched in Switzerland in May
- Approved by EC/EMA in June and positively recommended for VTE by NICE in July
- Launch readiness in Germany, Ireland and UK
- Sales forecast: 1.7 JPY Bn

Other region

 Applications for approval are underway in Taiwan, Korea and Brazil, and an application for approval was filed in Thailand in July

LCM

 The Hokusai-VTE Cancer study for patients with venous thromboembolism associated with cancer was initiated in June




R&D Topics

Major R&D pipeline

As of July 2015





Update on major late phase products PLX3397: FMS/KIT/FLT3-ITD inhibitor



Initiated new clinical trials

Tenosynovial Giant Cell Tumor (TGCT) Phase 3 study

- Initiated in May 2015
- Result of the Phase 1 study was published in NEJM in July 2015
 - 12 out of 23 patients (52 %) achieved a partial response (PR) and
 7 patients (30 %) had stable disease (SD)
- NDA targeted for FY2018 and approval for FY2019 in US/EU
- Combination with PD-1 inhibitor pembrolizumab Phase 1/2 study in collaboration with Merck
 - Initiated in July 2015
 - Rationale: to attack cancer cells in different immune-related systems
 - Target cancer: advanced melanoma and multiple other solid tumors
 - Part1: investigation of safety of PLX3397 in combination
 Part 2: extension cohort at the RP2D

Update on major late stage products Quizartinib: FLT3-ITD inhibitor



QuANTUM-R* Phase 3 study in progress

* Quizartinib Advancement into the Next Generation of Trial for Unmet Needs in AML

- Second-line therapy for relapsed or refractory FLT3-ITD-positive acute myeloid Leukemia
- Determine overall survival rate (primary outcome measure) and event-free survival rate (secondary outcome) with quizartinib vs. salvage chemotherapy
- Expect high efficacy and safety with low dose
- US/EU: NDA targeted for FY2017 and approval targeted for FY2018

<Reference> increased safety at lower dose without affecting efficacy

	Phase 2b low dose		Phase 2				
	30 mg/day (N=38)	60 mg/day (N=38)	90 mg/day (N=57)	135 mg/day (N=67)	200 mg/day (N=12)		
Best response							
CRc rate	47 %	47 %	47 %	45 %	42 %		
PR rate	13 %	24 %	25 %	28 %	50 %		
Maximum cha	nge in QTcF fr	om baseline (n	nsec)				
≤30	50 %	44 %	9 %	9 %	0 %		
>30 to ≤ 60	47 %	36 %	46 %	51 %	8 %		
>60	3 %	19 %	46 %	39 %	92 %		

CRc=CR+CRp+CRi (CRc: composite complete response, CR: complete remission, CRp: complete remission with incomplete platelet recovery, CRi: complete remission with incomplete hematologic recovery), PR: partial response

Update on major late stage products



CL-108*: Hydrocodone combination with less Opioid-Induced Nausea and Vomiting, OINV

Phase 3 studies on track, NDA in FY2015

 Novel, bi-layered tablet provides anti-emetic activity prior to hydrocodone effect

Hydrocodone 7.5 mg / Acetaminophen 325 mg

Promethazine 12.5 mg (Rapid release)

- Phase 3 studies to confirm effect on moderate to severe acute pain as well as the reduction of OINV
 - Post tooth extraction pain: completed
 - CL-108, compared to HC/APAP demonstrated a significant reduction in OINV CL-108 36% vs. HC/APAP 58% (p<0.001)
 - Osteoarthritis of the knee or hip pain
 - completed enrollment in April 2015
 - Pain associated with bunionectomy : on schedule
- US NDA: Targeted for FY2015
 *Exclusive license for US commercialization
 from Charleston Laboratories Inc.
 18

Update on major late stage products Mirogabalin: α2δ ligand



Phase 3 studies in each region : on track

US/EU: Fibromyalgia

- Three phase 3 studies for fibromyalgia: in progress
- NDA: targeted for FY2017 Approval: targeted for FY2019

JP/Asia: Peripheral Neuropathic Pain

- Phase 3 studies for diabetic peripheral neuropathic pain and postherpetic neuralgia: in progress
- NDA: targeted for FY2017 Approval: targeted for FY2018

Contact address regarding this material

Daiichi Sankyo Co., Ltd. Corporate Communications Department

TEL: +81-3-6225-1126

Financial forecasts, future projections and R&D information that Daiichi Sankyo discloses may include information that might be classified as "Forward Looking Statement". These forward looking statements represent our current assumptions basis on information currently available. Please note that such are subject to a number of known and unknown risk and uncertainties and our future performance may differ from the expectations as expressed in such statements.